TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06422325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC closed-loop system in insulin only mode
Description: The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC closed-loop system in insulin/pramlintide mode
Description: The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
Study: NCT05407012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the barrier enhancing preparation.
Description: Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
Study: NCT05335304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group 1
Description: Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group 2
Description: Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group 3
Description: Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group 4
Description: Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
Study: NCT05271253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: 0.25% bupivacaine is injected in the caudal epidural space

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: injection of normal Saline
Study: NCT04697537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided regional anesthesia
Description: Applied perineurally preoperatively ultrasound guided regional anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Applied in the wound intraoperatively from the orthopedics
Study: NCT04521946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study: NCT02603458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074
Description: Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
Study: NCT06403982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of oxytocin after ELA
Description: The use of oxytocin will be continued after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor.~Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Discontinuation of oxytocin after ELA
Description: The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor. If no progress is detected due to the secondary weakening of uterus contractile function, the oxytocin will be reintroduced. Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.
Study: NCT05989763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA)
Description: TEA will then be administrated for 1 hour twice daily for a period of 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-TEA
Description: Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
Study: NCT05700786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful compassion for perfectionism
Description: The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful compassion for perfectionism
Description: The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
Study: NCT06279598

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: This concerns a form of psychotherapy for PTSD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization Reprocessing (EMDR)
Description: This concerns a form of psychotherapy for PTSD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: This concerns a form of psychotherapy for PTSD.
Study: NCT05393531

Intervention type: DEVICE
Group type: OTHER
Intervention: Mandibular advancement device (MAD)
Description: Active therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: Active therapy
Study: NCT05068323

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Digital electroencephalography (EEG) for an hour (16 channels)
Description: Digital electroencephalography (EEG) for an hour (16 channels)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital electroencephalography (EEG) for an hour (16 channels)
Description: Digital electroencephalography (EEG) for an hour (16 channels)
Study: NCT04802512

Intervention type: PROCEDURE
Intervention: validity and reability study
Description: validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)

Intervention type: PROCEDURE
Intervention: validity and reability study
Description: validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
Study: NCT06400576

Intervention type: OTHER
Intervention: Headphone and Smartphone Intervention
Description: Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
Study: NCT04749888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted nurse-led home visiting
Description: The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
Study: NCT05032677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Epidural Technique
Description: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle
Description: 25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
Study: NCT05723536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Left Atrial Isolation
Description: Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter Ablation of Atrial Fibrillation
Study: NCT06284590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2/L19TNF
Description: Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
Study: NCT05171374

Intervention type: DRUG
Intervention: Dabrafenib
Description: Observational stusy. No intervention is planned

Intervention type: DRUG
Intervention: Dabrafenib
Description: Observational stusy. No intervention is planned

Intervention type: DRUG
Intervention: Trametinib
Description: Observational stusy. No intervention is planned

Intervention type: DRUG
Intervention: Trametinib
Description: Observational stusy. No intervention is planned
Study: NCT04881409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support with non-invasive ventilation (NIV)
Description: Patient with AECOPD is treated with NIV.
Study: NCT06406400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7.
Study: NCT06306196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® Recombinant Hepatitis E Vaccine
Description: 30㎍/dose, 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isotonic Sodium Chloride injection
Description: 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride injection
Description: 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isotonic Sodium Chloride injection
Description: 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride injection
Description: 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isotonic Sodium Chloride injection
Description: 0.5mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride injection
Description: 0.5mL administered intramuscularly
Study: NCT05774249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine
Description: while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline
Description: Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
Study: NCT05992844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KB Exercises Program
Description: Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Rehabilitation program
Description: Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation program
Description: Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
Study: NCT05739006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-201
Description: up to 8 treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda
Description: up to 8 treatment cycles
Study: NCT06164652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: walking with Ceriter Stride One
Description: Subjects walk on the GAITRite with the CSO insole in their shoes.
Study: NCT06406400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
Study: NCT06256094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a2 Platinum Premium Infant Formula Stage 1
Description: Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Frisolac Infant Formula Stage 1 (Dutch Edition)
Description: Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
Study: NCT06406400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
Study: NCT04671576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Powder, standard commercial infant formula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic Infant Formula
Description: Powder, organic milk-based infant formula.